The sensitivity and specificity of BALF EV-based EGFR genotyping in all stages were 76% and 87%, respectively, and the sensitivity was increased significantly according to each TNM stage reaching to 100% in stage IV metastatic NSCLC patients [26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.